Metformin-suppressed differentiation of human visceral preadipocytes: Involvement of microRNAs

KOJI FUJITA¹, HISAKAZU IWAMA², KYOKO OURA¹, TOMOKO TADOKORO¹, KAYO HIROSE¹, MIWAKO WATANABE¹, TEPEI SAKAMOTO³, AKIKO KATSURA¹, SHIMA MIMURA¹, TAKAKO NOMURA¹, JOJI TANI¹, HIISAOKI MIYOSHI¹, ASAHIRO MORISHITA¹, HIROHITO YONEYAMA¹, KEICHI OKANO³, YASUYUKI SUZUKI³, TAKASHI HIMOTO¹ and TSUTOMU MASAKI¹

¹Department of Gastroenterology and Neurology, Faculty of Medicine, ²Life Science Research Center, ³Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Miki, Kagawa 761-0793, Japan

Received April 8, 2016; Accepted August 31, 2016

DOI: 10.3892/ijmm.2016.2729

Abstract. Visceral adipose tissue contributes to the pathophysiology of metabolic syndrome. Metformin has been reported to suppress lipogenesis in a murine preadipocyte cell line. However, the effect of metformin on the differentiation of human visceral adipose tissue remains unknown. MicroRNAs (miRNAs or miRs) have been suggested as therapeutic targets because of their involvement in the differentiation and maturation of fatty cells. The aim of this study was to determine whether metformin suppresses the differentiation of human preadipocytes and to identify miRNAs associated with the regulation of lipid metabolism. Human visceral preadipocytes (HPrAD-vis) were preincubated in growth media and then cultured with differentiation media containing metformin for 1 or 2 weeks. Adipogenic differentiation of the cells was assessed by Oil Red O staining, and soluble adiponectin in the culture media was measured using an enzyme-linked immunosorbent assay. Cell proliferation was assessed using a WST-8 assay, and the gene and protein expression of peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT-enhancer-binding protein α (C/EBPα) was determined by RT-qPCR and western blot analysis, respectively. miRNAs were profiled using human miRNA Oligo chips after total RNA was extracted and labeled. Oil Red O staining showed that metformin suppressed the accumulation of lipid droplets in HPrAD-vis cells. The adiponectin concentration in the culture media was also decreased in metformin-treated cells. The WST-8 assay revealed no effect on proliferation or growth inhibition following metformin treatment, although metformin suppressed the expression of PPARγ and C/EBPα. miRNA profiling further revealed differences between the metformin-treated group and control HPrAD-vis cells. Thus, the findings of the present study demonstrated that metformin suppressed the differentiation of human preadipocytes in vitro and altered the miRNA profile of these cells. Thus, the miRNAs whose expression levels were altered by metformin may contribute to the observed suppression of HPrAD-vis cell differentiation.

Introduction

Visceral adipose tissue contributes to the pathophysiology of metabolic syndrome, which includes conditions such as insulin resistance, hypertension, hyperlipidemia and hyperuricemia (1,2). The basic strategy to treat metabolic syndrome is diet and exercise to prevent patients from cardiovascular disease and diabetes mellitus (3). However, visceral obesity negates efforts to cut down on the energy supply and metabolize excess energy (1). Medication or surgery is considered when lifestyle alteration fails, although the indication for bariatric surgery is limited to severely obese cases and those complicated with organ failure (4). Thus, the majority of metabolic syndrome cases with no response to diet and exercise are treated with medication.

Metformin is an oral biguanide drug that was introduced into clinical practice in the 1950s for the treatment of type 2 diabetes (5). Although metformin has been reported to suppress lipogenesis in a murine preadipocyte cell line, in contrast to thiazolidinedione, which induces the maturation of preadipocytes (6,7), the effect of metformin on human visceral adipose tissue has not been clearly demonstrated.

MicroRNAs (miRNAs or miRs) have been suggested as therapeutic targets in metabolic syndrome due to their role in the maturation of fat cells and the differentiation of adipocytes from mesenchymal stromal stem cells (8-10). The aim of the present study was to determine whether metformin suppresses the differentiation of human visceral adipocytes.
preadipocytes and to identify miRNAs associated with the regulation of lipid metabolism in these cells.

Materials and methods

Reagents. Primary antibodies for peroxisome proliferator-activated receptor γ (PPARγ) (cat. no. ab27649) and CCAAT-enhancer-binding protein α (C/EBPα) (cat. no. ab40761) were supplied by Abcam (Cambridge, UK). The primary antibody for β-actin (cat. no. AC-15) was obtained from Sigma Aldrich (St. Louis, MO, USA). The primers and probes used in RT-qPCR for PPARγ (Assay ID: Hs01115513_m1), C/EBPα (assay ID: Hs00269972_s1) and β-actin (assay ID: Hs01060665_s1) were supplied by Life technologies (Carlsbad, CA, USA).

Cell line and culture. Poietics™ human visceral preadipocytes (HPrAD-vis) were purchased from Lonza (Walkersville, MD, USA). Cells were plated and subcultured according to the manufacturer's instructions. Briefly, the cells were suspended in growth media at 1x10^5 cells/ml, and 1.5 ml of the cell suspension was seeded in 6-well dishes. The cells were incubated for 24 h. For the treated group, 1.5 ml of differentiation media (containing insulin, dexamethasone, indomethacin and isobutylmethylxanthine) including 2 or 10 mM metformin was added to the growth media in each well, yielding final concentrations of metformin of 1 and 5 mM, respectively. As a control, 1.5 ml of differentiation media without metformin was added to the control cells in growth media. Cells or media were harvested at the indicated time points.

Oil Red O staining. Adipogenic differentiation of the cells was assessed with Oil Red O staining as previously described (11). The cells were washed with PBS and fixed in 4% paraformaldehyde for 10 min. The cells were then washed with 3% isopropanol, followed by staining with newly filtered Oil Red O staining solution for 10 min. After washing with distilled water, the cells were destained in 100% isopropanol for 15 min. The stained area was measured using Image J (NIH, Bethesda, MD, USA).

Enzyme-linked immunosorbent assay for adiponectin in culture media. The adiponectin concentration in the culture media was measured using an enzyme-linked immunosorbent assay with human Adiponectin/Acrp30 (R&D systems, Minneapolis, MN, USA) (12). The assay was performed according to the manufacturer's protocol.

Cell proliferation assay. Cell proliferation was evaluated using a WST-8 assay, as previously described (13,14). Briefly, cell growth was measured with 10% WST-8 (Dojindo Laboratories, Tokyo, Japan) in a microplate reader according to the absorbance at 450 nm at the indicated time point.

RT-qPCR. Reverse-transcription and qPCR were performed to measure changes in messenger RNA (mRNA) expression following metformin treatment. Taqman® Gene Expression Assays (Life Technologies) were used to determine the expression level of mRNAs, and β-actin was used as an internal control. mRNAs were reverse transcribed using the Taqman® RNA Reverse Transcription kit (Life Technologies) according to the manufacturer's protocol. Briefly, total RNA was extracted using the RNeasy Mini Kit (Qiagen, Venlo, The Netherlands) and diluted to 1.0 ng/µl. Reverse transcription was performed in a 20 µl reaction volume consisting of 10 µl of RNA, 2 µl of 10X RT random primers and 8 µl of reverse transcription master mix. As a result, 0.5 ng/µl of cDNA was produced per tube. The PCR reaction was performed in a final volume of 20 µl, consisting of 2 µl of cDNA (0.5 ng), 1 µl of 20X qPCR assay mix, 7 µl of nuclease-free water and 10 µl of Taqman® Fast Universal Master mix according to the manufacturer's protocol. The cDNA was amplified and quantified using StepOnePlus™(Life Technologies). The mRNA expression levels were standardized to β-actin.

miRNA array analysis. Total RNA of cultured cells was extracted using the miRNAeasy Mini kit (Qiagen) as previously described (13,14,16-21). The samples were labeled using a miRCURY Hy3 Power Labeling kit (Exiqon, Vedbaek, Denmark) and hybridized onto a human miRNA Oligo chip, version 14.0 (Toray Industries Inc., Tokyo, Japan). Scanning was conducted using a 3D-Gene Scanner 3000 (Toray Industries Inc.). 3D-Gene extraction software (ver. 1.2, Toray Industries Inc.) was used to read the raw intensity of the image. The raw data were analyzed with GeneSpringGX ver. 10.0 (Agilent Technologies, Santa Clara, CA, USA) and quantile normalized (22). The fold-changes in miRNA expression level between the treated and control groups were calculated. Hierarchical clustering was accomplished using the furthest neighbor method and Pearson's product-moment correlation coefficients as a metric.

Results

Metformin suppresses the differentiation of preadipocytes with no proliferative effect on the cells. We studied the effect of metformin on the maturation of HPrAD-vis cells through morphological analysis with Oil Red O staining. Metformin (1 and 5 mM) significantly reduced lipid droplet accumulation in preadipocytes, as shown in Fig. 1A and B.

We also analyzed adiponectin secretion by measuring the concentration in the culture media. As shown in Fig. 1C, metformin decreased the adiponectin concentration on days 7 and 14 of culture. However, according to the WST-8 assay, metformin did not have any proliferative or growth-inhibitory effect on the cells.
We then examined whether the expression levels of key genes involved in adipocyte differentiation (PPARγ and C/EBPα) were altered by metformin. The mRNA expression of PPARγ and C/EBPα was downregulated by metformin treatment on day 7 (Fig. 1D). Downregulation of C/EBPα translation was confirmed by western blot analysis (Fig. 1E). These experiments were repeated three times, and identical results were obtained.

Differences in miRNA expression in HPrAD-vis cells cultured in vitro with and without metformin. Using custom microarrays, we analyzed the expression of human miRNAs in HPrAD-vis cells treated with or without 5 mM metformin. As shown in Table I, for HPrAD-vis cells treated with or without 5 mM metformin, 6 miRNAs were significantly upregulated after 1 week of metformin treatment, while 13 miRNAs were downregulated. After 2 weeks of 5 mM metformin treatment, 27 miRNAs were significantly upregulated and 6 miRNAs were downregulated compared to the control (Table II). As shown in Tables I and II, 2 upregulated miRNAs (miR-3687 and miR-1246), 4 downregulated miRNAs including miR-378 family members were observed in the cells cultured for 1 and 2 weeks with metformin. The expression level of miR-1246 increased in a time-dependent manner.

Table I. Statistical results and chromosomal locations of miRNAs in HPrAD-vis cells treated with 5 mM metformin for 1 week compared to control cells (P<0.05).

| Name         | Fold-change (treated/control) | SD   | P-value | Location |
|--------------|------------------------------|------|---------|----------|
| miR-664a-5p  | 2.57                         | 0.406| 0.0090  | 1        |
| miR-3687a    | 2.34                         | 0.910| 0.0229  | 21       |
| miR-4664-3p  | 2.30                         | 0.904| 0.0153  | 8        |
| miR-1246a    | 1.78                         | 0.363| 0.0107  | 2        |
| miR-4783-3p  | 1.74                         | 0.183| 0.0010  | 2        |
| miR-4656     | 1.58                         | 0.266| 0.0019  | 7        |
| miR-1539     | 0.64                         | 0.362| 0.0136  | 18       |
| miR-148b-3p  | 0.64                         | 0.198| 0.0109  | 12       |
| miR-4638-3p  | 0.63                         | 0.165| 0.0170  | 5        |
| miR-515-5p   | 0.62                         | 0.325| 0.0205  | 19       |
| miR-134      | 0.61                         | 0.273| 0.0313  | 14       |
| miR-939-5p   | 0.60                         | 0.239| 0.0360  | 8        |
| miR-378a-3p  | 0.54                         | 0.069| 0.0004  | 5        |
| miR-378i     | 0.49                         | 0.090| 0.0115  | 22       |
| miR-422a     | 0.45                         | 0.066| 0.0068  | 15       |
| miR-425-3p   | 0.42                         | 0.185| 0.0420  | 3        |
| miR-661      | 0.42                         | 0.307| 0.0244  | 8        |
| miR-615-5p   | 0.40                         | 0.233| 0.0481  | 12       |
| miR-3160-3p  | 0.21                         | 0.019| 0.0037  | 11       |

miRNAs were matched to miRNAs extracted from cells treated with 5 mM metformin for 2 weeks as shown in Table II. miRNAs, microRNAs; HPrAD-vis, human visceral preadipocytes; SD, standard deviation.

We then examined whether the expression levels of key genes involved in adipocyte differentiation (PPARγ and C/EBPα) were altered by metformin. The mRNA expression of PPARγ and C/EBPα was downregulated by metformin treatment on day 7 (Fig. 1D). Downregulation of C/EBPα translation was confirmed by western blot analysis (Fig. 1E). These experiments were repeated three times, and identical results were obtained.
Unsupervised hierarchical clustering analysis, using Pearson's correlations, showed that HPrAD-vis cells treated in vitro for 1 or 2 weeks with metformin clustered separately from the untreated cells (Fig. 2). The subset of 19 miRNAs in HPrAD-vis cells treated for 1 week with metformin and the 33 miRNAs detected in HPrAD-vis cells treated for 2 weeks were found to exhibit >1.5-fold alterations in the expression levels between the metformin-treated and control groups. These microarray data are registered at the NCBI Gene Expression Omnibus (GEO) under accession number GSE55665.

Discussion

In the present study, metformin suppressed lipid accumulation and adiponectin secretion with no suppression of cell growth. In addition, the expression levels of PPARγ and C/EBPα in HPrAD-vis cells were altered following treatment, indicating that metformin suppressed the differentiation of human preadipocytes (6,23,24). Additionally, the miRNA profiles of metformin-treated preadipocytes and control cells showed differential clustering. In particular, the expression of miR-1246 and miR-3687 increased following metformin administration, while the expression of miR-378 family members was decreased.

Differentiation of preadipocytes is associated with the accumulation of lipid droplets in the cells. Preadipocytes differentiate in mature fatty cells when they are exposed to an excess energy supply, such as through overnutrition (7). Mature adipocytes secrete several types of adipokines, including adiponectin (23). Additionally, the differentiation of adipocytes from mesenchymal stromal stem cells is characterized by alterations in genes such as PPARγ and C/EBP (25). Indeed, PPARγ and C/EBPα are representative of the genes upregulated in preadipocytes during the differentiation process from preadipocytes to mature adipocytes (24).

In a previous report, metformin was shown to suppress lipid droplet accumulation in murine preadipocytes (6). Similarly, in the present study, human preadipocytes showed reduced lipid accumulation without a decrease in cell numbers. Furthermore, the secretion of adiponectin, the mRNA expression of PPARγ and C/EBPα and the protein expression of
C/EBP in human preadipocytes decreased under metformin administration, similar to previous findings on murine preadipocytes (6). Collectively, our results suggest that metformin inhibits the differentiation of human preadipocytes.

Adipocyte differentiation is regulated via miRNAs; these small non-coding RNAs target the mRNAs of genes involved in each step of the differentiation from mesenchymal stromal stem cells to mature adipocytes (26). miRNAs are evolutionarily endogenous non-coding RNAs that have been identified as post-transcriptional regulators of gene expression. miRNAs bind mainly to the 3' untranslated regions (UTRs) of target mRNAs, resulting in mRNA degradation or the blockade of mRNA translation (27,28). Thus, miRNAs play crucial roles in the differentiation, maturation and intracellular metabolism of cells and the effects of various drugs, as shown in the findings of the present study (13,14,16-21). Several miRNAs have been shown to contribute to lipid metabolism (8), with roles for miRNAs reported for lipid synthesis, metabolism, transportation and storage.

In the present study, upregulation of miR-1246 and miR-3687 and downregulation of the miR-378 family were found to be involved in the differentiation of preadipocytes. Mice genetically lacking miR-378 family members are known to be resistant to high-fat diet-induced obesity (10).
In addition, miR-378 family members were found to be downregulated in murine preadipocytes, the differentiation of which was suppressed by metformin treatment (29). Therefore, metformin may exert its inhibitory effect on visceral adipocytes via downregulation of the miR-378 family.

Our data further suggest that the upregulation of miR-1246 and miR-3687 and downregulation of miR-422a are associated with the effect of metformin on the inhibition of preadipocyte differentiation. To the best of our knowledge, this report is the first to describe the association between three miRNAs above and lipid metabolism. Notably, mice and rats lack miR-1246, miR-3687 or miR-422a. Thus, the murine in vitro model was not used to examine the expression levels of these miRNAs following metformin treatment. The significance of miR-1246, miR-3687 and miR-422a in adipogenesis and the maturation of preadipocytes thus remains to be investigated.

In a previous study, miR-137 was shown to play a role in the differentiation of preadipocytes (30). However, our results showed that miR-137 expression was not altered during the differentiation of preadipocyte cells. Thus, the role of miR-137 in preadipocyte maturation should be investigated further in future studies.

In conclusion, metformin suppresses the maturation of human preadipocytes in vitro and altered the miRNA profile of cells. In particular, our results identify miR-1246, miR-3687 and miR-422a as promising therapeutic targets for the treatment of visceral obesity.

References

1. Kaar J: A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014: 943162, 2014.
2. Al-Daghri NM, Al-Attas OS, Alokail MS, Alkhafry KM, Charalampidis P, Livadas S, Kollias A, Sabico SL and Chrousos GP: Visceral adiposity index is highly associated with adiponectin values and glycaemic disturbances. Eur J Clin Invest 43: 183-189, 2013.
3. Simmons RK, Alberti KG, Gale EA, Colagiaro S, Tuomilehto J, Qiao Q, Ramachandraan T, Tajima N, Brajkovich Mirchov I, et al: The metabolic syndrome: Useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 53: 600-605, 2010.
4. O’Brien PE, MacDonald L, Anderson M, Brennan L and Brown WA: Long-term outcomes after bariatric surgery: A systematic review of the bariatric surgical literature. Ann Surg 257: 87-94, 2013.
5. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R and Matthews DR: Management of hyperglycemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55: 1577-1596, 2012.
6. Alexandre KB, Smit AM, Grant RP and Crowther NJ: Metformin inhibits intracellular lipid accumulation in the murine pre-adipocyte cell line, 3T3-L1. Diabetes Obes Metab 10: 688-690, 2008.
7. Liang J, Fu M, Ciociola E, Chandalia M and Abate N: Role of ENPP1 on adipocyte maturation. PLoS One 2: e882, 2007.
8. Fernández-Hernando C, Ramírez CM, Goedeke L and Suárez Y: MicroRNAs in metabolic disease. Arterioscler Thromb Vasc Biol 33: 178-185, 2013.
9. Gao Y, Xue J, Li X, Jia Y and Hu J: Metformin regulates osteoblast and adipocyte differentiation of rat mesenchymal stem cells. J Pharm Pharmacol 60: 1695-1700, 2008.
10. Carrer M, Liu N, Guerrer CE, Williams AH, Frisard MI, Hulver MW, Bassel-Duby R and Olson EN: Control of mitochondrial metabolism and systemic energy homeostasis by microRNAs 378 and 378*. Proc Natl Acad Sci USA 109: 15330-15335, 2012.
11. Wilson B, Lioita L and Petricoinii E: Dynamic protein pathway activation mapping of adipose-derived stem cell differentiation implicates novel regulators of adipocyte differentiation. Mol Cell Proteomics 12: 2522-2531, 2013.
12. Berg AH, Combs TP and Scherer PE: ACRP30/adiponectin: An adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13: 84-89, 2002.
13. Katoh K, Gong J, Iwama H, Kitanaka A, Tani J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, et al: The anti-diabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther 11: 549-560, 2012.
14. Fujita K, Iwama H, Sakamoto T, Okura R, Kobayashi K, Takano J, Katsura A, Tatsuta M, Maeda E, Mimura S, et al: Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo. Int J Oncol 46: 2497-2505, 2015.
15. Masaki T, Okada M, Tokuda M, Shiratori Y, Hatase O, Shirai M, Nishio K and Omata M: Reduced C-terminal Src kinase (Csk) activities in hepatocellular carcinoma. Hepatology 29: 379-384, 1999.
16. Miyoshi H, Kato K, Iwama H, Maeda E, Sakamoto T, Fujita K, Toyota Y, Tani J, Nomura T, Mimura S, et al: Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. Int J Oncol 45: 322-332, 2014.
17. Kobayashi M, Kato K, Iwama H, Fujihara S, Nishiyama N, Mimura S, Toyota Y, Nomura T, Nomura K, et al: Antitumor effect of metformin in esophageal cancer: In vitro study. Int J Oncol 42: 517-524, 2013.
18. Fujimori T, Kato K, Fujihara S, Iwama H, Yamashita T, Kobayashi K, Kamada H, Morishita A, Kobara H, Mori H, et al: Antitumor effect of metformin on cholangiocarcinoma: In vitro and in vivo studies. Oncol Rep 34: 2987-2995, 2015.
19. Fujihara S, Kato K, Morishita A, Iwama H, Nishioka T, Chiyo T, Nishiyama N, Miyoshi H, Kobayashi M, Kobara H, et al: Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo. Int J Oncol 46: 2172-2180, 2015.
20. Kato K, Iwama H, Yamashita T, Kobayashi K, Fujihara S, Fujimori T, Kamada H, Kobara H and Masaki T: The antidiabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo. Study of the microRNAs associated with the antitumor effect of metformin. Oncol Rep 35: 1582-1592, 2016.
21. Fujita K, Kobara H, Mori H, Fujihara S, Chiyo T, Matsunaga T, Nishiyama N, Ayaki M, Yachida T, Morishita A, et al: Differences in miRNA expression profiles between GST and leiomyma in human samples acquired by submucosal tunneling biopsy. Endosc Int Open 3: E665-E671, 2015.
22. Bolstad BM, Irizarry RA, Astrand M and Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193, 2003.
23. Bertore E, Scudiero O, Monaco ML, Palmieri A, Mazzarella G, Costagliola C, Bianco A and Daniele A: New insight into adipocyte nectin role in obesity and obesity-related diseases. BioMed Res Int 2014: 658913, 2014.
24. Wu Z, Rosen ED, Brun R, Hauser S, Adelmann G, Troy AE, McKeon C, Darlington GJ and Spiegelman BM: Cross-Fermentation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell 3: 151-158, 1999.
25. Nakagami H: The mechanism of white and brown adipocyte differentiation. Diabetes Metab J 37: 85-90, 2013.
26. Son YH, Ka S, Kim AE and Kim JB: Regulation of adipocyte differentiation via MicroRNAs. Endocrinol Metab (Seoul) 29: 122-135, 2014.
27. Callegari E, Elamin BK, Sabbioni S, Gramantieri L and Negrini M: Role of microRNAs in hepatocellular carcinoma: A clinical perspective. Oncotargets Ther 6: 1167-1178, 2013.
28. Kerr TA, Korenblat KM and Davidson NO: MicroRNAs and liver disease. Transl Res 157: 241-252, 2011.
29. Gerin I, Bommer GT, McCoin CS, Sousa KM, Krishnan V and MacDougald OA: Roles for miRNA-378/378* in adipocyte gene expression and lipogenesis. Am J Physiol Endocrinol Metab 299: E198-E206, 2010.
30. Shin KK, Kim YS, Kim JY, Bae YC and Jung JS: miR-137 controls proliferation and differentiation of human adipose tissue stromal cells. Cell Physiol Biochem 33: 758-768, 2014.